Saebo

Saebo operates in medical devices and rehabilitation technology, with a focus on stroke survivors and people recovering from neurological or orthopedic injuries. Its differentiation is breadth across the recovery pathway: the portfolio includes hand assistance through SaeboGlove, upper-limb support through SaeboMAS, gait support through SaeboStep, and sensory or functional electrical stimulation through the SaeboStim line. The company also targets both clinicians and home users, which gives it a wider route to market than a device designed solely for institutional rehabilitation. In the broader market context, Ekso Bionics, Hocoma, and Medtronic were named with Saebo in a 2024 rehabilitation-assistive-robotics article, but that listing does not establish equivalent products or a direct competitive relationship. Saebo’s positioning therefore appears centered on comparatively accessible, drug-free rehabilitation equipment and clinician-informed usability, supported by 10 granted patents and four registered trademarks.

Saebo was founded in 2001 and has developed a multi-product rehabilitation platform over roughly two decades. The Jun 1, 2022 equity crowdfunding round, totaling $592,631, is the only documented financing event and marks the clearest disclosed capital inflection point. This breadth may support cross-selling between clinical and home-rehabilitation users, but there is not enough public information to quantify revenue growth, utilization, or market share. The company is categorized in the 11–50 employee range, while only one current employee record is identified, creating uncertainty around the precision of workforce data. A Sep 20, 2024 industry reference placed Saebo within the rehabilitation assistive-technology landscape, though it did not report a new commercial milestone. Overall, Saebo shows sustained product development, but limited disclosed financing and hiring data make its growth rate difficult to determine.